Media coverage about Kite Pharma (NASDAQ:KITE) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kite Pharma earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.9127410681276 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern’s analysis:
- Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company – CTech (calcalistech.com)
- Kite Pharma (KITE) vs. Its Rivals Head-To-Head Survey (americanbankingnews.com)
- REFILE-Gilead to buy Cell Design Labs for up to $567 million (reuters.com)
- UPDATE 1-Gilead to buy Cell Design Labs for up to $567 mln (businessinsider.com)
- Gilead Sciences to Acquire Cell Design Labs for $567 Million – Yahoo Finance (finance.yahoo.com)
Kite Pharma (NASDAQ:KITE) traded up $0.20 during trading on Tuesday, hitting $179.99. 100 shares of the stock were exchanged, compared to its average volume of 1,652,408. Kite Pharma has a one year low of $39.82 and a one year high of $179.99.
In other news, SVP Jeffrey Wiezorek sold 5,283 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $179.66, for a total value of $949,143.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Shawn Tomasello sold 4,203 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $755,110.98. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,936 shares of company stock valued at $8,791,842. Company insiders own 14.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Kite Pharma (KITE) Earns Daily Media Sentiment Score of 0.20” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/12/kite-pharma-kite-earns-daily-media-sentiment-score-of-0-20.html.
About Kite Pharma
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
What are top analysts saying about Kite Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kite Pharma and related companies.